A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

NCT ID: NCT07143812

Last Updated: 2026-01-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-23
• Study Completion Date: 2026-12-31

Brief Summary

This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.

Detailed Description

Glioblastoma is a highly aggressive and rapidly progressing malignant brain tumor classified as a grade IV glioma. Despite the current standard of care, including surgical resection, radiation therapy, chemotherapy, and tumor treating fields, prognosis remains poor due to high recurrence rates, tumor heterogeneity, treatment resistance, and limited drug penetration across the blood-brain barrier. Moreover, glioblastoma often exhibits rapid tumor regrowth during the postsurgical recovery period when few therapeutic options are available.

This study investigates MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell product genetically modified to express a suicide gene. The product is administered intratumorally in newly diagnosed glioblastoma patients following surgical resection. The primary objective of the study is to evaluate the safety, tolerability, and maximum tolerated dose of MSC11FCD. Secondary objectives include the assessment of preliminary efficacy signals. The study aims to explore the potential of this novel therapeutic approach to selectively target residual tumor cells and potentially delay or prevent early recurrence, thereby contributing to improved patient outcomes and quality of life.

Conditions

Glioblastoma (GBM); Newly Diagnosed Glioblastoma Multiforme

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

The investigational drug into the Intratumoral administration

The investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery

Group Type: OTHER

MSC11FCD

Intervention Type: DRUG

Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery.

Interventions

MSC11FCD

Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients aged 19 to 70
• Patients diagnosed with newly diagnosed glioblastoma based on medical imaging after receiving standard therapy for glioblastoma
• Patients whose expected survival period is at least 3 months
• Patients who have not received any other types of immunotherapy
• Patients who have been given a sufficient explanation of the purpose and details of the clinical trial and the characteristics of the investigational drug from an investigator and who signed the consent form or had a legal guardian or representative sign the consent form prior to the beginning of this clinical trial

Exclusion Criteria

• Patients with recurrent glioblastoma. Known Dihydropyrimidine Dehydrogenase (DPD) deficiency Contraindications to contrast-enhanced MRI (e.g., patients with pacemakers or other reasons preventing MRI scans according to the study schedule)
• Patients who received Gliadel wafer implantation during surgery
• Patients with severe dysfunction of major organs (liver, kidney, bone marrow, lung, heart) as determined by the investigator
• Patients with concurrent malignancies other than glioblastoma or a history of malignancy within the past 5 years
• Patients with uncontrolled hypotension or hypertension
• Patients with serious infections as determined by the investigator, including sepsis, hepatitis A, B, or C
• Patients with a Karnofsky Performance Scale (KPS) score < 50
• Patients with autoimmune diseases involving the central nervous system (e.g., multiple sclerosis, myasthenia gravis, acute disseminated encephalomyelitis)
• Patients with a history of allergy to flucytosine (5-FC), its excipients, or 5-fluorouracil (5-FU)
• Pregnant or breastfeeding women, patients planning to become pregnant during the study period, or those unwilling to use appropriate contraception
• Participation in another clinical trial within 30 days prior to enrollment
• Any condition that, in the opinion of the investigator, would make the patient unsuitable for study participation

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CHA University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jaejoon Lim, PhD

Role: PRINCIPAL_INVESTIGATOR

CHA University

Locations

Bundang CHA Medical Center

Seongnam, Kyunggido, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Jaejoon Lim, PhD

Role: CONTACT

einses218@gmail.com

+82-31-780-5688

Facility Contacts

Jaejoon Lim, M.D., Ph.D

Role: primary

einses218@gmail.com

82-31-780-5688

Other Identifiers

MSC11FCD

Identifier Type: -

Identifier Source: org_study_id